12:00 AM
 | 
Jul 01, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

U300: Phase III data

The open-label, international Phase III EDITION I trial in 807 Type II diabetics showed that once-daily subcutaneous U300 as an add-on to mealtime insulin met the primary endpoint of non-inferiority to once-daily Lantus glargine as an add-on to mealtime insulin in reducing mean HbA1c from baseline to 6 months (0.83% for both). U300 also met the secondary endpoint of a lower...

Read the full 294 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >